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cancer, prevents up-regulation of ephrin B1 gene
expression and phosphorylation of NR2B via
suppression of interleukin-1 b production in a
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Abstract
Background: Z-360 is an orally active cholecystokinin-2 (CCK2)/gastrin receptor antagonist currently under
development as a therapeutic drug for pancreatic cancer. It was previously reported that Z-360 treatment in
combination with gemcitabine prolonged the survival period in a lethal pancreatic cancer xenograft model in
mice. In a phase Ib/IIa clinical study, Z-360 treatment displayed a trend of reduced pain in patients with advanced
pancreatic cancer in combination with gemcitabine including analgesics such as opioids. Here, we investigated the
mechanism of analgesic action of Z-360 in a severe cancer-induced pain model in mice, which is considered to be
opioid-resistant, by examining ephrin B1 gene expression, N-methyl-D-aspartate receptor NR2B subunit
phosphorylation, and interleukin-1b (IL-1b) production.
Results: In a mouse model of cancer-induced pain, ephrin B1 gene expression in dorsal root ganglia (DRGs) and
the phosphorylation of NR2B in the spinal cord were induced. Z-360 treatment inhibited both ephrin B1 gene
expression and the phosphorylation of NR2B. In addition, IL-1b production increased in the cancer-inoculated hind
paw of mice, but could be suppressed by treatment with Z-360. Moreover, we observed that the CCK1 receptor
antagonist devazepide similarly suppressed up-regulation of ephrin B1 gene expression and IL-1b production, and
that the intraperitoneal injection of sulfated CCK-8 induced the production of IL-1b in the cancer-inoculated region.
Conclusions: We have identified a novel pain cascade, in which IL-1b production in cancer-inoculated regions
induces ephrin B1 gene expression in DRGs and then ephrin B1 enhances the tyrosine phosphorylation of NR2B via
Eph B receptor in the spinal cord. Notably, Z-360 relieves cancer-induced pain by preventing this pain cascade
through the suppression of IL-1b production, likely via the blockade of CCK1 receptor. The pre-clinical results
presented here support the analgesic action of Z-360 in pancreatic cancer patients with severe, opioid-resistant
pain. Pre-clinical and clinical results have demonstrated that Z-360 combined with gemcitabine represents a
promising pancreatic cancer therapy approach with characteristic analgesic effects in addition to the prolongation
of survival.
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Background
Patients with cancer develop diverse symptoms, among
which pain is a major factor that can drastically reduce
quality of life [1-3]. Pancreatic cancer, in particular, is
often accompanied by severe pain, with 90% of patients
reporting significant pain [4]. Cancer-induced pain is
typically relieved with opioids, such as morphine, non-
opioid analgesics, such as acetaminophen, and nonster-
oidal anti-inflammatory drugs; however, these drugs are
not uniformly effective and undesirable side effects often
limit their use [5]. For these reasons, it is therefore
desirable to develop novel medical agents with increased
efficacy and safety for combating cancer-induced pain.
Z-360, calcium bis [(R)-(-)-3-[3-{5-cyclohexyl-1-(3,3-
dimethyl-2-oxo-butyl)-2-oxo-2,3,4,5-tetrahydro-1H-
benzo[b][1,4]diazepin-3-yl}ureido]benzoate], is an orally
active 1,5-benzodiazepine derivative cholecystokinin-2
(CCK2)/gastrin receptor antagonist that is currently
under development for the treatment of pancreatic can-
cer [6]. In pre-clinical studies, Z-360 inhibited pancrea-
tic cancer growth and prolonged survival in
combination with gemcitabine, a first line drug for the
treatment of pancreatic cancer, in mouse pancreatic
cancer xenograft models [7-9]. Z-360 was safe, well tol-
erated, and showed a trend towards reduced pain in
phase Ib/IIa clinical study patients with advanced pan-
creatic cancer when used in combination with gemcita-
bine and analgesics, such as opioids [6].
In a previous pre-clinical study, we evaluated the
analgesic effect of Z-360 using a mouse model of can-
cer-induced pain that was generated by the orthotopic
transplantation of B16/BL6 melanoma cells into the
plantar region of the right hind paw of C57BL/6 mice
[10]. This model induced licking behaviour (an indicator
of spontaneous pain), and mechanical allodynia and
hyperalgesia in the periphery of the melanoma mass
were observed from approximately day 10 after trans-
plantation [11,12], with intensities that were a notable
feature of this model. The mechanical allodynia and
hyperalgesia occurring at a late phase in this model
were considered to be resistant to existing analgesics,
including opioids and adjuvant analgesics [11-13], which
is similar to the resistance displayed by moderate-to-
severe pain of cancer patients. Therefore, the effects of
Z-360 on cancer-induced pain were examined in this
model, and it was found that it displayed an analgesic
effect that was attributed to the blockade of CCK1
receptor [10]. Moreover, we observed that the combina-
tion of Z-360 and morphine were more effective than
when each were administered alone. For these reasons,
the analgesic effect of Z-360 on cancer-induced pain
model in mice is considered to be associated with the
observed clinical benefit of Z-360 for pain relief against
opioid-resistant pancreatic cancer pain [6]. Despite the
evidence from these studies, the detailed analgesic
mechanism of Z-360 is unclear.
Recent studies suggest that ephrin B-Eph B receptor
signalling in dorsal root ganglia (DRGs) contributes to
activation of the N-methyl-D-aspartate (NMDA) recep-
tor [14,15] and plays a critical role in neuropathic pain
[16,17] and inflammatory hyperalgesia [14]. We specu-
late that ephrin B-Eph B receptor signalling in DRGs is
also involved in cancer-induced pain, as this type of
pain is both neuropathic and inflammatory [12]. Inter-
leukin-1b (IL-1b) is a major inflammatory cytokine
that has diverse effects on the immune system and is
considered to be relevant to cancer development,
owing to high levels of serum IL-1b [18,19] and ele-
vated gene expression [20,21] in cancer patients.
Recently, it was reported that IL-1b gene promoter
single nucleotide polymorphisms (IL-1b secretory phe-
notype) are associated with an increased risk for pan-
creatic cancer [19] and that IL-1b participates in
opioid-resistant pain, such as bone cancer and neuro-
pathic pain [22-27]. Zhang et al. also reported that
spinal IL-1b facilitated bone cancer pain [24], and the
intraneural administration of IL-1b into rat sciatic
nerves induced signs of neuropathic pain [22]. Conver-
sely, the administration of IL-1b inhibitors exhibited
anti-hypernociceptive action in different models of
neuropathic pain [26,27]. Based on these results, IL-1b
is considered to be a critical factor in the development
of opioid-resistant pain, such as cancer-induced pain.
Based on the results of these studies, we therefore
hypothesised that ephrin B-Eph B receptor signalling
and IL-1b play a role in cancer-induced pain.
In this study, we attempted to determine the mechan-
ism by which Z-360 mediates analgesic effects using a
mouse model of cancer-induced pain and examining
ephrin B-Eph B receptor signalling in DRGs, NMDA
receptor NR2B subunit phosphorylation, and IL-1b
production.
Results
Ephrin B1 gene expression in DRGs was induced in a
cancer-induced pain model in mice
In order to identify the factors that are associated with
cancer-induced pain, we first examined the expression
of several genes involved in the ephrin signalling path-
way, including ephrin A1, ephrin A2, ephrin B1, ephrin
B2, and the Eph A1 and Eph B1 receptors, in the DRGs
of six-week old C57BL/6 mice injected with B16/BL6
melanoma cells into the plantar region of the right hind
paw. As determined by quantitative real-time RT-PCR,
the gene expression of ephrin B1 in lumbar (L) 4-5
DRGs was induced 1.8 fold in cancer-induced pain mice
compared to normal control mice on day 15 after mela-
noma transplantation (p < 0.001) (Figure 1A); however,
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no change was observed for the Eph B1 receptor (Figure
1B). The expression of other examined genes (ephrin
A1, A2, B2 and Eph A1 receptor) were also not induced
(data not shown).
Effect of Z-360 on ephrin B1 gene expression in a cancer-
induced pain model in mice
After demonstrating that ephrin B1gene expression was
up-regulated in DRGs of mice injected with B16/BL6
melanoma cells, the effect of Z-360 treatment was
examined. Z-360 (100 mg/kg) was administered orally
once a day beginning on day 7 to day 14 after transplan-
tation, because the analgesic effect of Z-360 in cancer-
induced pain was confirmed most strongly by repeated
administration of a dose of 100 mg/kg [10]. On day 14
after transplantation, the expression of the ephrin B1
and Eph B1 receptor genes in L4-5 DRGs were exam-
ined (Figure 2A, B). Repeated administration of Z-360
suppressed the gene expression of ephrin B1 by 70.7%
compared with the vehicle-treated group in cancer-
induced pain mice (p < 0.001) (Figure 2A). The gene
expression of the Eph B1 receptor was unchanged in all
of the test groups (Figure 2B).
Effect of Z-360 on NR2B phosphorylation in cancer-
induced pain model in mice
Several tyrosine residues in the C-terminal cytoplasmic
region of NR2B have been shown to be phosphorylated
by Src family tyrosine kinases in vitro [28], with Tyr-
1472 being the major phosphorylation site. As it has
been reported that ephrin B2 induces phosphorylation
of Tyr-1472 residues [14], we next investigated
whether Tyr-1472 phosphorylation of NR2B was
enhanced in the spinal cord of the mouse model of
cancer-induced pain. The level of phosphorylated Tyr-
1472 NR2B in the vehicle control in cancer-induced
pain mice was 210% higher than the normal control
samples (p < 0.05) (Figure 3A, B); however, the
repeated administration of Z-360 (100 mg/kg) once a
day from day 7 to 14 after transplantation suppressed
phosphorylation by 62.5% compared with the vehicle
control (p < 0.05) (Figure 3A, B).
IL-1b levels increased in the cancer-inoculated region of
the right hind paw in the mouse model of cancer-induced
pain and was suppressed by Z-360 treatment
To investigate the effects of increased gene expression of
ephrin B1 in the mouse model of cancer-induced pain,
we examined the change in the inflammatory mediator
IL-1b in the cancer-inoculated region of the right hind
paw by double sandwich enzyme-linked immunosorbent
assay (ELISA). We found that IL-1b levels were signifi-
cantly increased in these regions of cancer-induced pain
mice compared with normal mice (p < 0.01) (Figure
4A). However, the administration of Z-360 (100 mg/kg)
once a day from day 7 to 14 after transplantation
significantly reduced the levels of IL-1b protein in the
cancer-inoculated region by 54.3% compared to the
vehicle-treated group in cancer-induced pain mice
Figure 1 Ephrin B1 and Eph B1 receptor gene expression in
DRGs from cancer-induced pain mouse model. B16/BL6
melanoma cells were injected into the plantar region of the right
hind paw of C57BL/6 mice. L4-5 dorsal root ganglion (DRG) samples
were taken on day 15 after transplantation. Gene expression
analyses for ephrin B1 (A) and the Eph B1 receptor (B) were
performed by quantitative real-time RT-PCR. Data represent fold
changes versus the mean for normal mice. Columns represent the
mean ± S.E. (n = 6). ###, p < 0.001, normal versus B16/BL6
melanoma (t-test).
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(p <0.05) (Figure 4B). This data suggested that Z-360
suppressed the production of IL-1b. In addition, the
effect of Z-360 on tumour size was assessed at day 14
after transplantation. The tumour size of the Z-360-trea-
ted group was similar to that of vehicle-treated group
(data not shown), indicating that Z-360 had no effect on
tumour size in this cancer-induced pain model in mice.
Effect of IL-1b injection into the right hind paw on the
gene expression of ephrin B1
To confirm whether IL-1b induced the gene expression
of ephrin B1 in L4-5 DRGs, we injected IL-1b (300 and
1000 pg/paw) directly into the plantar region of the
right hind paw of eight-week old C57BL/6 mice, and
examined the expression of the ephrin B1 and Eph B1
receptor genes in L4-5 DRGs after 60 min. It was
revealed that IL-1b injection (1000 pg/paw) into the
plantar region of the right hind paw significantly
induced the gene expression of ephrin B1 in L4-5 DRGs
(p < 0.05), but not the Eph B1 receptor (Figure 5A, B).
The injection IL-1b at 300 pg/paw had no effect on
either ephrin B1 or Eph B1 receptor gene expression.
Effects of devazepide on ephrin B1 gene expression and
IL-1b production
In our previous study, repeated oral administration of
devazepide, a CCK1 receptor antagonist, showed a simi-
lar anti-allodynic effect in the mouse model of cancer-
induced pain to that of Z-360 [10]. Here, we examined
the effects of devazepide on ephrin B1 gene expression
in DRGs and the level of IL-1b in the cancer-inoculated
region in the cancer-induced pain model in mice. Deva-
zepide (10 mg/kg) was administered orally once a day
from day 7 to 14 after transplantation, and gene expres-
sion of ephrin B1 and the Eph B1 receptor in L4-5
DRGs and the amount of IL-1b protein in the cancer-
inoculated region were then measured. The repeated
administration of devazepide significantly suppressed the
expression of the ephrin B1 gene compared with the
vehicle-treated group in cancer-induced pain mice (p <
0.01) (Figure 6A); however, the gene expression of the
Eph B1 receptor was unchanged in all of the test groups
(Figure 6B).
The amount of IL-1b protein in the cancer-inoculated
region was reduced by 25.8% in the devazepide-treated
group compared with vehicle-treated group (Figure 6C).
The p-value of the Wilcoxon test compared with the
vehicle-treated group was 0.08. The effect of devazepide
on tumour size was assessed at day 14 after transplanta-
tion and no differences in the tumour size were detected
between the control and devazepide-treated group (data
not shown).
Sulfated cholecystokinin-8 induced IL-1b production in
the cancer-inoculated region
To determine whether CCK contributed to the
increased levels of IL-1b in the cancer-inoculated region,
we examined the effect of sulfated CCK-8 injection on
IL-1b production. Sulfated CCK-8 (10 and 30 μg/kg)
Figure 2 Effects of Z-360 on ephrin B1 and Eph B1 receptor
gene expression in DRGs. B16/BL6 melanoma cells were injected
into the plantar region of the right hind paw of C57BL/6 mice, and
Z-360 (100 mg/kg) was then administered orally once a day from
day 7 after transplantation. A final oral administration of Z-360 was
given to mice 60 min prior to the collection of L4-5 DRG samples
on day 14 after transplantation. Gene expression analysis for ephrin
B1 (A) and the Eph B1 receptor (B) were performed by quantitative
real-time RT-PCR. Data represent -fold changes versus the mean for
normal mice. Columns represent the mean ± S.E. (n = 12). ###, p <
0.001, versus normal (t-test). ***, p < 0.001, versus vehicle (t-test).
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was intraperitoneally injected into the mouse model of
cancer-induced pain twice a day beginning from day 7
after transplantation, and the final injection was per-
formed 30 min prior to the collection of paw samples
on day 10. The levels of IL-1b protein in the cancer-
inoculated regions were then measured by ELISA, which
revealed that the administration of sulfated CCK-8
increased the amount of IL-1b protein compared with
that of the vehicle-treated control group (p < 0.01) (Fig-
ure 7). The levels of IL-1b between the saline, 10 μg-,
and 30 μg-sulfated CCK-8 treatment groups were 227.4,
862.0, and 719.1 pg/g tissue, respectively.
Discussion
In this study, we discovered a novel pain cascade asso-
ciated with the analgesic action of Z-360 in a mouse
model of cancer-induced pain. In this cascade, IL-1b
production from cancer-inoculated regions induces the
gene expression of ephrin B1 in DRGs, which then
ephrin B1 enhances the tyrosine phosphorylation of
NR2B via Eph B receptor in the spinal cord, finally lead-
ing to pain. Z-360 was found to inhibit this pain cas-
cade, suggesting that Z-360 reduces cancer-induced pain
through the suppression of IL-1b production in cancer-
inoculated regions, which in turn inhibits ephrin B1
gene expression, and tyrosine phosphorylation of NR2B.
The pre-clinical results presented here indicate that Z-
360 may provide relief against severe, opioid-resistant
pain in patients with advanced pancreatic cancer.
In the cancer-induced pain model used in this study,
it was reported that bradykinin and related peptides
released from melanoma cells might cause spontaneous
pain and allodynia [29]; however, we identified that the
enhancement of IL-1b production, which may be predo-
minantly released from immune cells invading tissues
surrounding tumours, is another potential factor for
causing pain. We demonstrated that IL-1b increased in
cancer-inoculated regions and induced the expression of
the ephrin B1 gene in the periphery of DRGs. We also
found that the tyrosine phosphorylation of NR2B in the
spinal cord was enhanced in the cancer-induced pain
model in mice. The activation of the NMDA receptor is
essential for the development of chronic inflammatory
and neuropathic pain [30-32]. As our present data sug-
gests that the novel pain cascade may be important for
the development of cancer-induced pain, we propose
that the components of this novel pain cascade, IL-1b
(cancer-inoculated region) ® ephrin B1 (DRGs) ®
NR2B (spinal cord), represent potential drug targets for
the treatment of cancer-induced pain.
In vitro experiments have revealed that Z-360 has affi-
nity for both recombinant human CCK2 and CCK1
receptors, with Kis of 0.47 and 316 nM, respectively [7].
In our previous study, the analgesic effect of CCK1
receptor antagonist, devazepide, was also observed after
repeated administration to the mouse model of cancer-
induced pain [10]. Here, devazepide (10 mg/kg) reduced
the level of IL-1b protein in cancer-inoculated regions,
and significantly suppressed the gene expression of
ephrin B1 in DRGs to a similar degree as Z-360. Cun-
ningham et al. reported that CCK induces the production
of inflammatory cytokines, including IL-1b, in monocytes
from peripheral blood [33]. We also confirmed here that
the intraperitoneal injection of sulfated CCK-8 (10 and
Figure 3 Effect of Z-360 on spinal cord NR2B phosphorylation in the mouse model of cancer-induced pain. A. NR2B was
immunoprecipitated from lysates of the spinal cord of cancer-induced pain model in mice. The immunoprecipitates were separated on 10%
SDS-PAGE gels and then transferred onto PVDF membranes with a Trans-Blot Cell System. The membranes were first probed with an antibody
against pTyr1472-NR2B, stripped, and then reprobed with an antibody against NR2B. The panels show representative immunoblots of normal
control, vehicle control, and Z-360 (100 mg/kg) treatment performed with antibodies against pTyr1472-NR2B (top) and NR2B (bottom). B.
Histograms showing the relative tyrosine phosphorylation of NR2B normalized to normal controls. Adobe Photoshop Elements 5.0 software was
used for densitometric quantification. Values represent the mean ± S.E. (n = 3). #, p < 0.05, normal versus vehicle (t-test); *, p < 0.05, vehicle
versus Z-360 (t-test).
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30 μg/kg) resulted in an increase in IL-1b production in
cancer-inoculated regions. Taken together, these results
suggest that Z-360 is able to suppress IL-1b production
via the blockade of CCK1 receptor.
In a previous pre-clinical study, Z-360 also exhibited
analgesic effects on formalin-induced pain [10], and
Honore et al. demonstrated that IL-1ab gene-deficient
mice display reduced nociceptive sensitivity to formalin-
induced pain [23]. Although the detailed mechanisms
Figure 4 IL-1b production in the cancer-inoculated region and
the effect by Z-360 treatment. A. B16/BL6 cells were injected into
the plantar region of the right hind paw of C57BL/6 mice. On day
14 after transplantation, right hind paw samples were collected,
homogenized, and subjected to an ELISA for the measurement of
IL-1b. The results are reported as the mean ± S.E. (n = 12). ##, p <
0.01, normal versus B16/BL6 melanoma (Wilcoxon test). B. Z-360
(100 mg/kg) was administered orally once a day from day 7 to 14
after transplantation. A final dose of Z-360 was orally administered,
and after 60 min, the levels of IL-1b were measured. The results are
reported as the mean ± S.E. (n = 23-24). ###, p < 0.001, normal
versus vehicle (Wilcoxon test); *, p < 0.05, vehicle versus Z-360
(Wilcoxon test).
Figure 5 Effects of IL-1b injection on ephrin B1 and Eph B1
receptor gene expression in DRGs. Recombinant IL-1b (300 or
1000 pg/paw) was injected into the plantar region of the right hind
paw of C57BL/6 mice, and L4-5 DRG samples were then collected
after 60 min. Gene expression analysis for ephrin B1 (A) and the Eph
B1 receptor (B) were performed by quantitative real-time RT-PCR.
Data represent fold changes versus the mean for saline-injected
control mice. Columns represent the mean ± S.E. (n = 4). *, p <
0.05, versus saline (non-parametric Dunnett’s test).
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are unclear, we speculate that Z-360 inhibits formalin-
induced pain via the suppression of IL-1b production. It
is also possible that other factors besides the suppres-
sion of IL-1b production participate in the analgesic
effects of Z-360 in these pain models. The group of
Grossi et al. reported that novel 1,5-benzodiazepine
derivatives, such as Z-360, display analgesic and/or anti-
inflammatory properties in spite of lacking affinities for
central and peripheral benzodiazepine receptors [34,35].
A few of the examined derivatives showed an analgesic
effect on acetic acid-induced writhing in mice, whereas
other derivatives inhibited leukocyte migration via the
suppression of nociceptive and/or inflammatory media-
tors, such as IL-6 and prostaglandin E2, in a carragee-
nan-induced air pouch model in mice. Furthermore,
although the target molecules of these activities were
not specified, it was found that a few derivatives had
both analgesic and anti-inflammatory activities with low
acute toxicity. These results indicate that Z-360 may be
able to mediate analgesic action through other mechan-
isms in addition to the inhibition of IL-1b production.
Recently, a number of 1,5-benzodiazepine derivatives
have been developed as drug candidates for diseases
associated with pain [36,37], inflammation [38,39], nerve
injury [40], and cardiovascular disorders [41]. Due to
the related nature of their structures, the characterised
chemical structure of Z-360 can provide important
information for the design and development of innova-
tive analgesics and anti-inflammatory agents.
In summary, we have identified a novel pain cascade,
IL-1b (cancer-inoculated region) ® ephrin B1 (DRGs)
® NR2B (spinal cord) ® pain, that may be responsible
for the development of opioid-resistant pain in the
mouse model of cancer-induced pain. Moreover, Z-360
inhibited the novel pain cascade through the suppres-
sion of IL-1b production. Accordingly, we consider that
Figure 6 Effects of devazepide on ephrin B1 and Eph B1 receptor gene expression and IL-1b production. B16/BL6 cells were injected
into the plantar region of the right hind paw of C57BL/6 mice, and devazepide (Deva, 10 mg/kg) was then administered orally once a day from
day 7 after transplantation. A final oral administration of devazepide was given to mice prior to the collection of L4-5 DRG and right hind paw
samples on day 14 after transplantation. Gene expression analyses for ephrin B1 (A) and the Eph B1 receptor (B) in DRGs were performed by
quantitative real-time RT-PCR. Data represent fold changes versus the mean for normal mice. Columns represent the mean ± S.E. (n = 12). ##, p
< 0.01, versus normal (t-test); **, p < 0.01, versus vehicle (t-test). C. Right hind paw samples were subjected to the extraction of IL-1b which was
then measured by ELISA. The data are reported as the mean ± S.E. (n = 12). ###, p < 0.001, normal versus vehicle (Wilcoxon test); p = 0.08
(devazepide treatment), vehicle versus devazepide (Wilcoxon test).
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the suppression of IL-1b production by Z-360 was criti-
cal for its ability to alleviate cancer-induced pain in a
previous clinical study [6].
Conclusions
This pre-clinical study identified a novel pain cascade
involving the release of IL-1b from a cancer-inoculated
region, induction of ephrin B1 gene expression in DRGs,
and subsequent enhancement of tyrosine phosphoryla-
tion of NR2B in the spinal cord. Notably, the oral
administration of Z-360 inhibited the novel pain cascade
through the suppression of IL-1b production. We con-
clude that the pre-clinical results presented here support
the relief action of Z-360 against severe, opioid-resistant
pain in patients with advanced pancreatic cancer. Pre-
clinical and clinical results have demonstrated that
Z-360 combined with gemcitabine is a safe and promis-
ing pancreatic cancer drug with characteristic analgesic
effects in addition to the prolongation of survival.
Methods
Animals
Five and seven-week-old male C57BL/6NCrlCrlj
(C57BL/6) mice were purchased from Charles River
Laboratories Japan, Inc. (Yokohama, Japan). Mice were
kept under controlled temperature (23 ± 3°C), humidity
(55 ± 20%), and lighting (lights on at 7:00 AM and of at
7:00 PM) conditions, and food and water were available
ad libitum. All experimental procedures were approved
by the Institutional Animal Care and Use Committee of
Zeria Pharmaceuticals Central Research Laboratories.
Samplings were carried out between 10:00 AM and
4:00 PM.
Drug
Z-360 was synthesized at the Central Research Labora-
tories of Zeria Pharmaceutical Co., Ltd. (Kumagaya,
Japan). Devazepide was purchased from Tocris
Bioscience Inc. (St. Louis, MO, USA). Z-360 and devaze-
pide were resuspended in a 0.5% (w/v) carboxymethyl
cellulose sodium solution before use.
Mouse model of cancer-induced pain
A mouse model of cancer-induced pain was made
according to the method of Sasamura et al [11]. Briefly,
B16/BL6 melanoma cells derived from C57BL/6 mice
(Cell Resource Center for Biomedical Research, Tohoku
University, Sendai, Japan) were cultured in RPMI1640
medium containing 10% fetal bovine serum at 37°C and
a humidified atmosphere of 5% CO2. Cells (2 × 10
5
cells/20 μL) were injected into the plantar region of the
right hind paw of six-week old C57BL/6 mice. Z-360
(100 mg/10 mL/kg) or devazepide (10 mg/10 mL/kg)
was administered orally once a day from day 7 to 14
after transplantation, and paw withdrawal thresholds
were measured on day 7 and 14. Z-360 or devazepide
(at the above-mentioned concentrations) was adminis-
tered orally 60 min prior to tissue sampling on day 14
after transplantation.
Preparation of DRG samples for gene expression analysis
On day 14 after transplantation, L4 and L5 DRG sam-
ples were taken from normal mice and the cancer-
induced pain mouse model. Two DRG bodies for each
sample were pooled and then homogenized with lysis
buffer from an RNeasy Micro Kit (QIAGEN, Hilden,
Germany) using a Tissue Lyser (QIAGEN) for the pre-
paration of total RNA.
Real-time quantitative RT-PCR
Total RNA was prepared from tissue lysate using an
RNeasy Micro Kit (QIAGEN). After purification, the
amount of RNA was measured spectrophotometrically
using OD260, and the quality of RNA was checked by
gel electrophoresis and spectrophotometric analysis
using OD260/280. Total RNA (100 ng) was converted
into first-strand cDNA by PrimeScript RT Reagent Kit
(Takara Bio Inc., Otsu, Japan). The resulting first-strand
Figure 7 Effect of sulfated CCK-8 on IL-1b production in the
cancer-inoculated region. B16/BL6 cells were injected into the
plantar region of the right hind paw of C57BL/6 mice, and sulfated
CCK-8 (10 or 30 μg/kg) was then administered by intraperitoneal
injection twice a day from day 7 after transplantation. On day 10
after transplantation, a final dose of sulfated CCK-8 was
administered to mice 30 min prior to the collection of right hind
paw samples, which were the homogenized and subjected to ELISA
for the measurement of IL-1b. The data are reported as the mean ±
S.E. (n = 11-12). ##, p < 0.01, versus saline (non-parametric Dunnett’s
test).
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cDNAs were subjected to real-time quantitative RT-PCR
with ABsolute™ QPCR ROX Mix (Thermofisher Scienti-
fic, Waltham, MA, U.S.A.) and TaqMan probes for
ephrin B1 (Mm00438666_m1) and the Eph B1 receptor
(Mm00557961_m1), using an ABI PRISM 7900HT
Sequence Detection System (Applied Biosystems, Foster
City, CA, U.S.A.). The cycling parameters were 15 min
at 95°C followed by 45 cycles of 15 sec at 95°C and 1
min at 60°C. The obtained data were normalized to the
expression of GAPDH (Mm99999915_g1) and analyzed
by the Comparative CT Method (Applied Biosystems).
Tyrosine phosphorylation of NR2B
The relative tyrosine phosphorylation of NR2B was
examined by immunoprecipitation. For the analysis, the
spinal cords from normal and cancer-induced pain
model mice were rapidly removed on day 14 after trans-
plantation. Z-360 (100 mg/kg) was administered orally
once a day beginning from day 7 after transplantation.
Tissues were homogenized in solubilization buffer con-
taining 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1
mM EDTA (pH 8.0), 1% NP-40, 0.1% sodium dodecyl
sulfate (SDS), 0.5% sodium deoxycholate, 1 mM sodium
vanadate (Na3VO4), 25 mM sodium fluoride (NaF), 1
mM PMSF, and protease inhibitor cocktail (Sigma-
Aldrich, St Louis, MO, U.S.A.) using a Tissue Lyser
(QIAGEN). After centrifugation at 12,000 rpm for 5 min
at 4°C, the supernatants containing the proteins were
collected and the protein concentrations were deter-
mined using the BCA Protein Assay (Bio-Rad Labora-
tories, Hercules, CA, U.S.A.). Equal amounts of proteins
were added to 0.6 μg of rabbit anti-NR2B antibody
(Millipore, Billerica, MA, U.S.A.) and gently shaken
overnight at 4°C. The following morning, Dynabeads
Protein G (Invitrogen, Carlsbad, CA, U.S.A.) were added
to the samples which were then gently shaken for 1 h at
4°C. Beads were then rinsed in solubilization buffer and
boiled in loading buffer (2% SDS, 50 mM Tris-HCl (pH
6.8), 200 mM b-mercaptoethanol, 10% glycerol, and
0.1% Bromophenol Blue) for 5 min. The protein-rich
supernatants were separated on a 7.5% Ready-gel J (Bio-
Rad Laboratories) and transferred to a polyvinylidine
difluoride (PVDF) membrane using a Trans-Blot Cell
System (Bio-Rad Laboratories). The membranes were
blocked for 1 h at room temperature with 3% non-fat
milk in Tris buffered saline containing 20 mM Tris-HCl
(pH 7.5), 150 mM NaCl, and 0.1% Tween20 (TBST) and
then incubated overnight at 4°C with rabbit anti-
phospho-tyr1472-NR2B antibody (1:1000, Upstate,
Cambridge, U.K.). After washing with TBST, membranes
were incubated for 1 h at room temperature with HRP-
rec-Protein G (1:8000, Invitrogen). All antibodies were
diluted in TBST. Protein bands were visualized using an
Enhanced Chemi-Luminescence Detection Kit (ECL
Plus, Amersham Pharmacia, Chalfont St.Giles, U.K.) fol-
lowed by autoradiography using Hyperfilm (Amersham
Pharmacia). The blots were then washed in TBST and
stripped for 30 min in stripping buffer containing 2%
SDS, 62.5 mM Tris-HCl (pH 6.8), and 100 mM b-mer-
captoethanol. The membranes were washed twice in
TBST for 30 min and then blocked for 1 h at room
temperature with 3% non-fat milk in TBST. Membranes
were reprobed for total NR2B by overnight incubation
at 4°C with rabbit anti-NR2B antibody (Millipore). Blots
were then washed, incubated for 1 h at room tempera-
ture with HRP-rec-Protein G (1:8000, Invitrogen), and
visualized as above. Hyperfilms were scanned and
captured using Adobe Photoshop Element 5.0 software
(Adobe Systema Inc., Scion Jose, CA, U.S.A.) for
densitometric quantification. We obtained the relative
phosphotyrosin-1472-NR2B band density (relative
pTyr1472-NR2B density) levels by normalizing the anti-
phosphotyrosine immunoblot against the corresponding
total NR2B immuoblot from identical samples.
IL-1b levels in the right hind paw
On day 14 after transplantation, we dissected the can-
cer-inoculated regions of right hind paw including B16/
BL6 melanoma or normal as sample. After measuring
their weight, samples were homogenized in 0.5 mL pro-
tein lysis buffer containing 10 mM Tris-HCl (pH 7.5),
150 mM NaCl, 1 mM EDTA (pH 8.0), 1% NP-40, 1
mM sodium vanadate (Na3VO4), 1 mM PMSF, and
protease inhibitor cocktail (Sigma-Aldrich) using an
Ultra-Turrax T25 (Janke & Kunkel, IKA Werk, Staufen,
Germany). After centrifugation at 3,000 rpm for 15 min
at 4°C, supernatants containing the proteins were col-
lected and IL-1b levels were determination by ELISA
(R&D Systems, Minneapolis, MN, U.S.A.).
IL-1b-inducible gene expression analysis in DRGs
Recombinant mouse IL-1b (R&D systems) (5 μL, 300 or
1000 pg/paw) was injected into the plantar region of the
right hind paw of eight-week old C57BL/6 mice. Sixty
min after the injection, L4-5 DRG samples were removed
and gene expression analysis and real-time quantitative
RT-PCR were performed as described above.
Sulfated CCK-8-induced IL-1b production
In the mouse model of cancer-induced pain, intraperito-
neal injection of 10 mL of sulfated CCK-8 per kg body
weight (10 or 30 μg/kg, Peptide Institute, Inc., Osaka,
Japan) was performed twice daily from day 7 after trans-
plantation. On day 10, the amounts of IL-1b protein in
the right hind paw samples were measured by ELISA as
described above. Sulfated CCK-8 was administered 30
min prior to the removal of the paw. In total, the injec-
tion of sulfated CCK-8 was performed seven times.
Orikawa et al. Molecular Pain 2010, 6:72
http://www.molecularpain.com/content/6/1/72
Page 9 of 11
Statistical analysis
All data are expressed as the mean ± standard error
(S.E.). Data were analyzed with SAS System Version 8.2
(SAS Institute Japan Ltd., Tokyo, Japan) using the t-test,
Wilcoxon signed-rank test, and non-parametric Dun-
nett’s test. Differences with a p-value of less than 0.05
were considered statistically significant.
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